MGMT expression in cohorts of patients
| MGMT expression | ||
| Negative (0/1) | Positive (2/3) | |
| Inherited CRC | ||
| HNPCC | ||
| Neo | 20/42 (47.6%) | 22/42 (52.4%) |
| A | 15/41 (36.6%) | 26/41 (63.4%) |
| D | 8/38 (21.1%) | 30/38 (78.9%) |
| FAP | ||
| Neo | 3/13 (23.1%) | 10/13 (76.9%) |
| A | 2/13 (15.4%) | 11/13 (84.6%) |
| D | 1/12 (8%) | 11/12 (92%) |
| Sporadic CRC | ||
| Neo | 49/89 (55.1%) | 40/89 (44.9%) |
| MSI | 28/40 (70%) | 12/40 (30%) |
| MSS | 21/49 (42.9%) | 28/49 (57.1%) |
| A | 40/74 (54.4%) | 34/74 (45.6%) |
| MSI | 18/30 (60%) | 12/30 (40%) |
| MSS | 22/44 (50%) | 22/44 (50%) |
| D | 30/81 (37%) | 51/81 (63%) |
| MSI | 9/35 (25.7%) | 26/35 (74.3%) |
| MSS | 21/46 (45.6%) | 25/46 (54.4%) |
| Controls | 2/20 (10%) | 18/20 (90%) |
| IBD-associated CRC | ||
| Neo | 36/49 (73.5%) | 13/49 (26.5%) |
| MSI | 12/13 (92.3%) | 1/13 (7.7%) |
| MSS | 24/36 (66.7%) | 12/36 (33.3%) |
| A | 21/33 (63.6%) | 12/33 (36.4%) |
| MSI | 10/10 (100%) | 0 (0%) |
| MSS | 11/23 (47.8%) | 12/23 (52.2%) |
| D | 29/38 (76.3%) | 9/38 (23.74%) |
| MSI | 9/10 (90%) | 1/10 (10%) |
| MSS | 20/28 (71.4%) | 8/28 (28.6%) |
| Controls | 29/39 (74.4%) | 10/39 (25.6%) |
A, adjacent mucosa; CRC, colorectal cancer; D, distant mucosa; FAP, familial adenomatous polyposis; HNPCC, hereditary non-polyposis colorectal cancer; IBD, inflammatory bowel disease; MGMT, O6-methylguanine DNA methyltransferase; MSI, microsatellite unstable; MSS, microsatellite stable; Neo, tumour.